Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.93 |
| ▸ | MEN1 | O00255 | 2/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.86 |
| ▸ | GLA | P06280 | 1/20 | 0.86 |
| ▸ | TSHR | P16473 | 3/20 | 0.69 |
| ▸ | KDM1A | O60341 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SAT1 | P21673 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | F13A1 | P00488 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | THPO | P40225 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylhomospermine SCHEMBL426504 | 1.00 | CYP2C19 (0.93) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL6899291 | 0.96 | CYP2C19 (1.00) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL4157457 | 0.96 | CYP2C19 (1.00) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL7513770 | 0.96 | CYP2C19 (0.87) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| Hydrochloric Acid SCHEMBL3877574 | 0.96 | CYP2C19 (0.87) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL7097560 | 0.96 | CYP2C19 (0.87) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL4167237 | 0.96 | CYP2C19 (1.00) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL7091884 | 0.96 | CYP2C19 (0.87) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL12085573 | 0.96 | CYP2C19 (0.87) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL7096788 | 0.96 | CYP2C19 (0.87) | CYP2C19CYP1A2MEN1KMT2AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937235-A2 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | Pathologica, LLC. (US) | 2008-07-02 | — | — | EP | claimed |
| US-20070078187-A1 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | PATHOLOGICA, LLC. (US) | 2007-04-05 | — | — | US | claimed |
| WO-2007035957-A2 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | PATHOLOGICA, LLC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-20030158262-A1 | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway | ALS THERAPY DEVELOPMENT FOUNDATION, INC. | 2003-08-21 | — | — | US | claimed |
| WO-2024192269-A2 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240309418-A1 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | MASSACHUSETTS GEN HOSPITAL (US) | 2024-09-19 | — | — | US | disclosed |
| US-20230338317-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | Orbus Therapeutics, Inc. | 2023-10-26 | — | — | US | disclosed |
| US-11439612-B2 | Formulations for administration of eflornithine | Orbus Therapeutics, Inc. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3971178-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | The McLean Hospital Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220008418-A1 | Aminoquinoline Derivatives and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | disclosed |
| EP-2822936-B1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | MCLEAN HOSPITAL CORP (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20030158262-A1 | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway | ALS THERAPY DEVELOPMENT FOUNDATION, INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030130357-A1 | Use of polyamine analogs for amyotrophic lateral sclerosis | ALS THERAPY DEVELOPMENT FOUNDATION, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030130350-A1 | Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis | ALS THERAPY DEVELOPMENT FOUNDATION, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030118539-A1 | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-06-26 | — | — | US | disclosed |
| WO-2003043616-A2 | TREATMENT OF NEURODEGENERATIVE DISORDERS THROUGH THE MODULATION OF THE POLYAMINE PATHWAY | ALS THERAPY DEVELOPMENT FOUNDATION, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003013245-A1 | POLYAMINES AND ANALOGS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-02-20 | — | — | WO | disclosed |
| EP-0886524-A2 | DELIVERY OF THERAPEUTIC AGENTS TO THE PROSTATE | CHIRON CORPORATION (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1997031611-A2 | TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | CHIRON CORPORATION (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008418-A1 | Aminoquinoline Derivatives and Uses Thereof | LRRK2, NLN, AADAT | CYP2C19 2780/4885CYP1A2 2110/4885MEN1 1524/4885 |
| US-20230338317-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | EFNA1, IDH1, ABCC5 | CYP2C19 816/4885CYP1A2 624/4885MEN1 664/4885 |
| US-20070078187-A1 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | GLS, SHMT2, ARG2 | CYP2C19 3039/4885CYP1A2 3619/4885MEN1 446/4885 |
| US-20030130350-A1 | Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis | ODC1, AOC1, OTC | CYP2C19 4630/4885CYP1A2 4531/4885MEN1 4307/4885 |
| US-20030158262-A1 | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway | ODC1, SRM, OTC | CYP2C19 4855/4885CYP1A2 4604/4885MEN1 4302/4885 |
| US-20030130357-A1 | Use of polyamine analogs for amyotrophic lateral sclerosis | ODC1, HNRNPC, NUDC | CYP2C19 4829/4885CYP1A2 4591/4885MEN1 3870/4885 |
| US-11439612-B2 | Formulations for administration of eflornithine | EFNA1, KMT5A, ETV1 | CYP2C19 868/4885CYP1A2 892/4885MEN1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.